Levodopa - Pharmacology
Research News and Information

Monday, November 23, 2009

Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.

14 Sep 2009 Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by selective loss of dopaminergic neurons in the pars compacta of the substantia nigra. Levodopa (l-dopa) and dopamine agonists have been most commonly used for ... Read more...

Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency.

23 Aug 2009 OBJECTIVE: To report the efficacy, tolerability, and safety of the dopamine agonist pramipexole in a series of 5 patients affected by inherited 6-pyruvoyl tetrahydropterin synthase (PTPS) deficiency and needing l-3,4 dihydroxyphenylalanine (l-dopa) ... Read more...

Amphetamine reduces vesicular dopamine content in dexamethasone-differentiated PC12 cells only following L-DOPA exposure.

20 Aug 2009 Amphetamine (AMPH) increases brain dopamine (DA) levels via reversal of the membrane DA transporter. Additional mechanisms have been suggested, including inhibition of vesicular monoamine transporters and vesicular leakage of DA and Ca(2+). ... Read more...

Latest indexed articles for 'Levodopa - Pharmacology'

These are the very latest articles for this heading:

• Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. 14 Sep 2009
• Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency. 23 Aug 2009
• Amphetamine reduces vesicular dopamine content in dexamethasone-differentiated PC12 cells only following L-DOPA exposure. 20 Aug 2009
• Visualizing vesicular dopamine dynamics in Parkinson's disease. 30 Jul 2009
• Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. 26 Jul 2009
• Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. 21 Jul 2009
• Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. 19 Jul 2009
• L-dopa medication in Parkinson's disease restores activity in the motor cortico-striatal loop but does not modify the cognitive network. 5 Jul 2009
• [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence] 29 Jun 2009
• Nicotinamide reduces dopamine in postnatal hypothalamus and causes dopamine-deficient phenotype. 15 Jun 2009
• Influence of subthalamic deep brain stimulation versus levodopa on motor perseverations in Parkinson's disease. 13 Jun 2009
• L-dopa modulates functional connectivity in striatal cognitive and motor networks: a double-blind placebo-controlled study. Jun 2009
• Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa). 30 May 2009
• Dopamine depletion induces distinct compensatory gene expression changes in DARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons. 25 May 2009
• Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats. 24 May 2009
• Changes of functional connectivity of the motor network in the resting state in Parkinson's disease. 18 May 2009
• Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism. 17 May 2009
• Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. 2 May 2009
• Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease. 29 Apr 2009
• L-DOPA attenuates hyperactivity of Roborovskii hamsters. 29 Apr 2009

See a longer list of these articles.

Technical information about 'Levodopa'

Definition: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.

Registry Number: 0

Descriptor UI: D007980

Alternative terms: Levodopa; L-Dopa; L Dopa; 3-Hydroxy-L-tyrosine; 3 Hydroxy L tyrosine; L-3,4-Dihydroxyphenylalanine; L 3,4 Dihydroxyphenylalanine; Levopa; Dopar; Roberts Brand of Levodopa; Larodopa; Roche Brand of Levodopa; Dopaflex; Medphano Brand of Levodopa;

Related Mesh Headings: Dopamine;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antiparkinson Agents; Dopamine Agents;

Tree Number: D02.092.311.200.480; D12.125.072.050.685.400.500; D12.125.072.050.875.130.500;

Online Note: search DOPA 1972-74

History Note: 75; was see DOPA 1972-74